Seqirus
Seqirus acts as anchor for the Liverpool City Region’s health and life science sector
About Seqirus
Derived from the expression ‘securing health for all of us’ Seqirus has public health protection at its core. This reflects the promise of its parent company CSL, founded in 1916 to save lives and protect the health of people. Seqirus draws on over a century of experience in influenza vaccines, and as such, is the only vaccine company with a singular global focus on influenza. The company utilises innovative research, transformative technologies, and the latest methods of production and distribution.
Having been based in Speke since 1947, Seqirus Liverpool has become the largest vaccine manufacturing facility in the UK, producing over 50m doses of seasonal influenza vaccine each year, with the ability to increase production to 200m doses in the event of an influenza pandemic. The site now has a high-speed fill-and-finish facility, which enables start-to-finish onshore manufacturing, where previously the vaccine would be sent abroad to be put into syringes.
Benefits of being born in the Liverpool City Region (LCR)
Throughout its 70-year-plus history in Liverpool, Seqirus has acted as a foundation to the Health and Life Science’s industry across the LCR, playing a key role in fostering an early ecosystem to encourage growth. Over the following decades, the LCR has gone on to become a hub for Health and Life Sciences and now inhabits a rich, collaborative network of businesses that support one another’s growth strategies.
Being based in such a well-established hub for Health and Life Sciences continues to open doors for those within the sector, including a deep talent pool of skilled workers. Seqirus works with universities from across the region including the University of Liverpool, Liverpool John Moore University and the University of Manchester, ensuring courses are tailored to the needs of the sector.
Seqirus Results to date
- Seqirus Liverpool has the ability to increase production to 200m from 50m doses in the event of a pandemic.
- Seqirus is the largest provider of seasonal influenza vaccines to the UK and a major global supplier. The new fill and finish facility will help meet growing global demand for seasonal influenza vaccines and helps with influenza pandemic preparedness for the UK.
- Seqirus Liverpool has shortened supply lead times by more than one to two weeks per batch.
- The new facility represents an investment of nearly £50m creating more than 120 high value jobs.
Support from Growth Platform and the LCR
As well as being Vice President of Manufacturing and Site Head at Seqirus Liverpool, Nige Hilton is a member on the Health and Life Science’s board for the Liverpool City Region. This ensures that Seqirus Liverpool remains aligned with the city region’s growth strategy and understands the areas requiring investment.
Seqirus continues to work closely with Growth Platform to engage with stakeholders from across public and private sector offices. This has proven effective as Seqirus has progressed through its business model, with the support received from Managing Director of Growth Platform Mark Basnett in opening doors to UK Government engagement and other major clients.
Reflecting upon the LCR and its talent pool, Vice President of Manufacturing and Site Head at Seqirus Liverpool, Nige Hilton, said, “Seqirus has benefitted from a long-history of success, with the Liverpool City Region and the people within it being key to this.”
“Seqirus could not have fulfilled its commitments to public health during the pandemic if hadn’t been for its incredible employees from across the region who, thanks to their self-effacing but genuine passion, pride and determination, came together to supply 30% more vaccine. These traits are something we really cherish as they will undoubtedly contribute to the future success of Seqirus and the region as a whole”.
“Seqirus could not have fulfilled its commitments to public health during the pandemic if hadn’t been for its incredible employees from across the region who, thanks to their self-effacing but genuine passion, pride and determination, came together to supply 30% more vaccine. These traits are something we really cherish as they will undoubtedly contribute to the future success of Seqirus and the region as a whole”.
Nige Hilton, Site Head at Seqirus Liverpool
Get in touch
Whatever your business ambition, requirement or opportunity – talk to one of our team to see how we can help. We are in the business of delivering value, success and excellence and we’re waiting to speak with you.
